Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Elsevier's 2023 Intravenous Medications

See next edition:

Elsevier's 2024 Intravenous Medications
Elsevier's 2024 Intravenous Medications

Elsevier's 2023 Intravenous Medications

9780323931809
231.79 zł
197.02 zł Save 34.77 zł Tax included
Lowest price within 30 days before promotion: 197.02 zł
Quantity
Product unavailable
Out of print

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Find the essential information you need to safely administer more than 400 intravenous drugs! For nearly 50 years, Elseviers Intravenous Medications:: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format. New to the 2023 edition are 10 monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.

Product Details
Elsevier
91949
9780323931809
9780323931809

Data sheet

Publication date
2022
Issue number
39
Cover
paperback
Pages count
1392
Weight (g)
1700
  • Evolve website information, inside front cover
    General Dilution Charts
    How to Use This Book
    Preface
    Format and Content of Intravenous Medications
    Key to Abbreviations
    Important IV Therapy Facts
    Resources
    IV Drugs
    Appendix A
    Recommendations for the Safe Use and Handling of Cytotoxic Drugs
    Appendix B
    FDA Pregnancy Categories
    Appendix C
    U.S. Department of Health and Human Services, National Institutes of Health, National
    Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)
    Appendix D
    Information for Patients Receiving Immunosuppressive Agents
    Appendix E
    Recently Approved Drugs
    Index
    Solution Compatibility Chart, last page and inside back cover
    Selected Agents Not Included in the Book, Evolve website
    Ado-trastuzumab
    Agalsidase Beta
    Alfentanil Hydrochloride
    Alglucerase
    Alglucosidase Alfa
    Alpha1-Proteinase Inhibitor (Human)
    Amifostine
    Ammonium Chloride
    Amobarbital Sodium
    Anthrax Immune Globulin Intravenous
    (Human)
    Antivenin (Latrodectus mactans)
    Antivenin (Micrurus fulvius)
    Antivenin Crotalidae Polyvalent Immune
    Fab (Ovine)
    Arginine Hydrochloride
    Ascorbic Acid
    Asparaginase Erwinia chrysanthemi
    Atracurium Besylate
    Axicabtagene Ciloleucel
    Azathioprine Sodium
    Blinatumomab
    Botulism Immune Globulin (Intravenous
    Human)
    Brentuximab
    Busulfan
    CONTENTS xv
    Caffeine and Sodium Benzoate
    Capreomycin
    Carfilzomib
    Centruroides (Scorpion) Immune F(ab)2
    (Equine) Injection
    Chloramphenicol Sodium Succinate
    Conjugated Estrogens
    Copanlisib
    Corticorelin Ovine Triflutate
    Crizanlizumab-tmca
    Crotalidae Immune F(ab9)2 (Equine)
    Dactinomycin
    Daratumumab
    Deferoxamine Mesylate
    Defibrotide
    Denileukin Diftitox
    Dextran 1
    Diazoxide
    Dimenhydrinate
    Diphtheria Antitoxin
    Dolasetron Mesylate
    Doxapram Hydrochloride
    Droperidol
    Edetate Calcium Disodium
    Edetate Disodium
    Elosulfase Alfa
    Elotuzumab
    Enfortumab Vedotin-ejfv
    Ethacrynic Acid
    Fam-Trastuzumab Deruxtecan-nxki
    Fospropofol Disodium
    Gallium Nitrate
    Galsulfase
    6% Hydroxyethyl Starch 130/0.4 in NS
    Idursulfase
    Imiglucerase/Velaglucerase Alfa
    Inamrinone Lactate
    Inotuzumab Ozogamicin
    Interferon Alfa-2b, Recombinant
    Ipilimumab
    Kanamycin Sulfate
    Laronidase
    Levocarnitine
    Lincomycin Hydrochloride
    Liothyronine Sodium
    Mechlorethamine Hydrochloride
    Meperidine Hydrochloride
    Methadone
    Methoxy Polyethylene Glycol-Epoetin Beta
    Methylene Blue
    Minocycline Hydrochloride
    Mogamulizumab-kpkc
    Obiltoxaximab
    Orphenadrine Citrate
    Oxacillin Sodium
    Pancuronium Bromide
    Pegaspargase
    Pentazocine (Lactate)
    Pentetate Calcium Trisodium/Pentetate
    Zinc Trisodium
    Phentolamine Mesylate
    Piperacillin Sodium
    Plasma Protein Fraction
    Pooled Plasma (Human)
    Pralidoxime Chloride
    Protein (Amino Acid) Products
    Protein C Concentrate (Human)
    Pyridostigmine Bromide
    Pyridoxine (Vitamin B6)
    Quinidine Gluconate Injection
    Raxibacumab
    Regadenoson
    Remifentanil Hydrochloride
    Rocuronium Bromide
    Sebelipase Alfa
    Secretin
    Sermorelin Acetate
    Siltuximab
    Sincalide
    Sipuleucel-T
    Sodium Lactate
    Sodium Nitrite and Sodium Thiosulfate
    Sodium Phenylacetate and Sodium
    Benzoate
    Streptokinase
    Streptomycin Sulfate
    Streptozocin
    Succinylcholine Chloride
    Taliglucerase Alfa
    Theophylline in D5W
    Ticarcillin Disodium and Clavulanate
    Potassium
    Tisagenlecleucel
    Trabectedin
    Trace Metals
    Treprostinil
    Vaccinia Immune Globulin Intravenous
    (Human)
    Verteporfin
    Vestronidase Alfa-vjbk Injection
    Ziv-Aflibercept

See next edition:

Elsevier's 2024 Intravenous Medications
Elsevier's 2024 Intravenous Medications
Comments (0)

  • Frequently purchased together

    No products available